179174-76-6

Basic information

• Product Name: 2-Butene-1,4-diol, 2-[4-(methylsulfonyl)phenyl]-3-phenyl-, (2Z)-
• CAS NO: 179174-76-6
• Molecular Formula: C17H18O4S
• Molecular Weight: 318.394
• Mol File: 179174-76-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Butene-1,4-diol, 2-[4-(methylsulfonyl)phenyl]-3-phenyl-, (2Z)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butene-1,4-diol, 2-[4-(methylsulfonyl)phenyl]-3-phenyl-, (2Z)-(179174-76-6)
• EPA Substance Registry System: 2-Butene-1,4-diol, 2-[4-(methylsulfonyl)phenyl]-3-phenyl-, (2Z)-(179174-76-6)

Safety Data

• Hazardous Substances Data: 179174-76-6(Hazardous Substances Data)

Upstream product

• 162011-90-7 rofecoxib 

Downstream Products

• 654068-92-5 (2Z)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-en-1-ol 
• 654069-08-6 3-({[tert-butyl(dimethyl)silyl]oxy}methyl)phenyl(2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl carbonate 
• 179174-77-7 (2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl acetate 

Relevant articles and documents

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx(TM))

Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx(TM)) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay

Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.